Celularity Secures $35M Strategic License Deal
Celularity announced it secured a $35 million strategic license deal for its placental-derived biomaterials portfolio. The deal, expected to close by April 15, aims to strengthen Celularity's capital position and advance its longevity-focused strategy.
The deal, expected to close by April 15, involves Celularity granting an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs. NexGel, Inc. is the counterparty in the agreement. The agreement includes a $15 million upfront payment and up to $20 million in net sales-based milestone payments. Celularity will retain exclusive manufacturing rights at its FDA-compliant facility in Florham Park, New Jersey, ensuring continued revenue from biomaterials. This arrangement allows Celularity to focus on its longevity-focused therapeutic pipeline, which includes allogeneic, cryopreserved cell therapies derived from the postpartum placenta. These therapies target age-related diseases. The company is undergoing an organizational realignment, including workforce reductions, to lower operating expenses and improve capital efficiency. In Q3 2025, Celularity reported a net revenue of $5.3 million, a 43.2% decrease compared to $9.3 million in the same quarter of 2024. The net loss for the quarter was $23.07 million. Celularity's biomaterial product pipeline includes Interfyl, Biovance, and CentaFlex. The company's most advanced program, PDA-002, targets diabetic foot ulcers, a complication disproportionately affecting older adults. Celularity went public in April 2021 via a SPAC transaction.
